Retrophin (RTRX) Given Daily Coverage Optimism Rating of 0.22

Media stories about Retrophin (NASDAQ:RTRX) have trended somewhat positive on Monday, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Retrophin earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.2667429827872 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

A number of brokerages have recently weighed in on RTRX. Zacks Investment Research downgraded Retrophin from a “hold” rating to a “sell” rating in a report on Thursday, January 11th. BidaskClub upgraded Retrophin from a “hold” rating to a “buy” rating in a report on Wednesday, January 10th. Finally, ValuEngine upgraded Retrophin from a “sell” rating to a “hold” rating in a report on Wednesday, March 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $44.00.

How to Become a New Pot Stock Millionaire

Shares of RTRX stock opened at $22.36 on Monday. Retrophin has a 1-year low of $15.55 and a 1-year high of $26.44. The company has a current ratio of 3.80, a quick ratio of 3.74 and a debt-to-equity ratio of 0.15. The firm has a market cap of $887.54, a PE ratio of -14.91 and a beta of 0.96.

Retrophin (NASDAQ:RTRX) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.20). Retrophin had a negative net margin of 38.55% and a negative return on equity of 13.98%. The business had revenue of $42.18 million for the quarter, compared to analysts’ expectations of $42.20 million. equities research analysts anticipate that Retrophin will post -1.59 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by WKRB News and is owned by of WKRB News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.wkrb13.com/2018/04/02/retrophin-rtrx-given-daily-coverage-optimism-rating-of-0-22.html.

Retrophin Company Profile

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Insider Buying and Selling by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply